洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展 To evaluate and compare the effectiveness of Coenzyme Q10 versus Vitamin E supplementation on serum testosterone levels, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.

【ChiCTR2600121913】To evaluate and compare the effectiveness of Coenzyme Q10 versus Vitamin E supplementation on serum testosterone levels, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.

查看原文
立即下载
基本信息
登记号

ChiCTR2600121913

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-04-07

临床申请受理号

/

靶点

/

适应症

Male infertility

试验通俗题目

To evaluate and compare the effectiveness of Coenzyme Q10 versus Vitamin E supplementation on serum testosterone levels, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.

试验专业题目

Effectiveness of Coenzyme Q10 versus Vitamin E in improving serum testosterone, luteinizing hormone levels and semen parameters in men with idiopathic primary infertility: A randomized controlled study

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

25000

联系人通讯地址
请登录查看
临床试验信息
试验目的

To compare the effectiveness of Coenzyme Q10 and Vitamin E supplementation in improving serum testosterone, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

其它

随机化

Participants were randomized into two groups using a computer-generated randomization sequence prepared by an independent investigator not involved in recruitment or assessment.

盲法

Open-label

试验项目经费来源

Institute of Kidney Diseases (IKD), Hayatabad Medical Complex

试验范围

/

目标入组人数

50

实际入组人数

/

第一例入组时间

2023-02-01

试验终止时间

2024-06-30

是否属于一致性

/

入选标准

1. Male patients aged 20–40 years; 2. History of primary infertility for more than one year despite regular unprotected intercourse; 3. Diagnosis of idiopathic infertility after clinical evaluation; 4. Normal semen parameters according to WHO manual 6th edition; 5. Willingness to participate and provide written informed consent.；

排除标准

1. Known endocrine or systemic disease; 2. History of cryptorchidism, varicocele, testicular hypotrophy, or genital tract infection; 3. Obstructive azoospermia or presence of antisperm antibodies; 4. Previous use of hormonal therapy or antioxidant supplements; 5. Female factor infertility in the partner.；

研究者信息
研究负责人姓名
请登录查看
试验机构

Department of Urology, Institute of Kidney Diseases (IKD), Hayatabad Medical Complex

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

25000

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Department of Urology, Institute of Kidney Diseases (IKD), Hayatabad Medical Complex的其他临床试验

更多

Institute of Kidney Diseases, Hayatabad Medical Complex, Phase 4, Peshawar, Khyber Pakhtunkhwa, Pakistan的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品